(NASDAQ)
68.82
+1.62   (+3.02%)
 
Volume (24h) Market Cap. Day Range 52w Range
85,401 1.71B 66.73 - 69.88 8.51 - 129.71
Jan-28-21 08:30AM Is the Options Market Predicting a Spike in Arcturus Therapeutics (ARCT) Stock?Zacks
Jan-23-21 04:40AM Thailand Approves AstraZeneca: Southeast Asia Vaccine TrackerBloomberg
Jan-12-21 06:51AM Is Arcturus Therapeutics a Buy?Motley Fool
Jan-07-21 03:19AM Why Arcturus Therapeutics Stock Skyrocketed TodayMotley Fool
Jan-06-21 03:59AM Did You Miss Out on the Chance for Big Gains from Arcturus Stock?Motley Fool
11:14AM Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline UpdatesZacks
Jan-06-21 08:00AM Arcturus Therapeutics to Present at Upcoming Investor ConferenceBusiness Wire
Jan-05-21 08:57AM Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine StudyZacks
07:27AM Why Is Everyone Talking About Arcturus Therapeutics Stock?Motley Fool
Jan-04-21 07:22AM Arcturus gets FDA go-ahead to begin Phase 2 trial for COVID-19 vaccine candidateMarketWatch
07:01AM Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United StatesBusiness Wire
Dec-31-20 07:32AM Time to Go Bargain Hunting on Arcturus Stock? Analyst Weighs InTipRanks
08:49AM Arcturus (ARCT) to Develop ARCT-032 for Cystic FibrosisZacks
Dec-30-20 12:34PM Arcturus to Develop Therapeutic Spray for Cystic FibrosisTheStreet.com
11:40AM Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & MoreZacks
Dec-30-20 11:22AM Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study ResultsZacks
07:00AM Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung DiseaseBusiness Wire
Dec-29-20 11:02AM Some Analysts Just Cut Their Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) EstimatesSimply Wall St.
05:35AM Markets Ease Lower as Arcturus, Blink Charging PlungeMotley Fool
Dec-29-20 05:11AM Novavax Starts a Phase 3 Trial for Its Covid Vaccine, While Arcturus Gets 5 Downgrades for Its StockBarrons.com
04:33AM Arcturus Reports Results From Early-Stage Testing of Its Coronavirus VaccineMotley Fool
Dec-29-20 04:23AM Why Arcturus Therapeutics Stock Crumbled On Its Covid Vaccine UpdateInvestor's Business Daily
03:27AM Tuesday’s 10 Notable Market Movers in the LimelightInsider Monkey
Dec-29-20 11:42AM Why Arcturus Therapeutics Stock Is Plunging TodayMotley Fool
11:12AM Why Arcturus Therapeutics Stock Crumbled On Its Covid Vaccine UpdateInvestor's Business Daily
Dec-29-20 10:23AM Arcturus Therapeutics shares slide 55% after COVID vaccine data are deemed ‘underwhelming’MarketWatch
09:59AM Arcturus Slumps Amid Analyst Pessimism on VaccineTheStreet.com
Dec-29-20 09:49AM Return On Capital Employed Overview: Arcturus TherapeuticsBenzinga
09:45AM Novavax Starts a Phase 3 Trial for Its Covid Vaccine, While Arcturus Gets 5 Downgrades for Its StockBarrons.com
Dec-29-20 08:57AM Arcturus Therapeutics shares slide 37% in premarket after COVID vaccine data are deemed ‘underwhelming’MarketWatch
08:09AM The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For OsmoticaBenzinga
Dec-28-20 04:01AM Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical DataBusiness Wire
Dec-23-20 11:23AM Why Arcturus Therapeutics Stock Is Sinking TodayMotley Fool
Dec-20-20 06:09AM 3 Incomparable Coronavirus Vaccine Stocks to Buy Right NowMotley Fool
Dec-19-20 10:10AM Is ARCT A Good Stock To Buy?Insider Monkey
Dec-16-20 06:14AM 3 COVID-19 Vaccine Stocks That Could Be the Biggest Winners in a Post-Pandemic WorldMotley Fool
Dec-13-20 02:02AM These 2 Early-Stage COVID Vaccines Could Be Game-ChangersMotley Fool
06:05AM 3 Top Coronavirus Stocks to Buy in DecemberMotley Fool
Dec-12-20 07:03AM Is It Too Late to Get in on This Millionaire-Maker Stock?Motley Fool
Dec-11-20 02:38AM If You Invested $10,000 in Arcturus in January, This Is How Much You'd Have NowMotley Fool
06:45AM These 5 Mid-Cap Healthcare Stocks Had the Best Gains in 2020Motley Fool
Dec-10-20 06:10AM Why You Might Want to Buy This Potentially Game-Changing COVID Vaccine Stock Right NowMotley Fool
Dec-08-20 06:20AM Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on TuesdayMotley Fool
Dec-07-20 11:30AM Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common StockBusiness Wire
11:18AM New Forecasts: Here's What Analysts Think The Future Holds For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Simply Wall St.
Dec-07-20 04:33AM Arcturus Therapeutics Announces Proposed Public Offering of Common StockBusiness Wire
07:00AM Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) DeficiencyBusiness Wire
Dec-05-20 06:12AM Here's the Dark Horse in the COVID Vaccine Race That You'll Want to WatchMotley Fool
Nov-30-20 06:00AM Arcturus Therapeutics to Present at Upcoming Investor ConferenceBusiness Wire
Nov-23-20 08:40AM Morning Bell With Jim Cramer: Buy General ElectricTheStreet.com
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Ltd. has a strategic collaboration with CureVac AG to jointly discover, develop, and commercialize novel messenger RNA therapeutics. The company was founded in 2013 and is headquartered in San Diego, California.
Cap:    |  Volume (24h):